Researcher
Piet Ost
- Keywords:Radiotherapy, Prostate Cancer
- Disciplines:Cancer therapy, Palliative care and end-of-life care, Urology, Radiation therapy
Affiliations
- Department of Human Structure and Repair (Department)
Member
From1 Oct 2018 → Today - Dean's Office of the Faculty of Medicine and Health Sciences (Administrative office)
Member
From1 Jul 2012 → 30 Sep 2012 - Department of Radiation oncology and experimental cancer research (Department)
Member
From1 Nov 2008 → 30 Sep 2018
Projects
1 - 10 of 13
- Omics analysis in liquid biopsy samples of advanced tumoursFrom1 Nov 2023 → TodayFunding: BOF - doctoral mandates
- Digital pathology as a proxy for molecular profiling of prostate tumorsFrom1 Oct 2022 → TodayFunding: BOF - projects
- Detection of biomarkers to reduce radiation-induced toxicities and improve clinical outcomes, with emphasis on the role of unintended dose.From1 Sep 2022 → 31 Aug 2023Funding: Nonprofit institution or equivalents
- Study of the molecular mechanisms of metastasis in prostate cancer.From1 Oct 2021 → 31 Jan 2022Funding: BOF - doctoral mandates
- ProBio: an outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker-driven trial in patients with metastatic castration-resistant prostate cancerFrom1 Feb 2020 → 31 Jan 2024Funding: Nonprofit institution or equivalents
- A data-driven integrative framework for the identification of cancer driver pathways and their mode of action.From1 Nov 2019 → 31 Oct 2023Funding: FWO Strategic Basic Research Grant
- CHEckpoint inhibition in combination with an immunoboost of External body adiotherapy in oligometastatic or oligoprogressive Solid tumors: CHEERS-trialFrom1 Jul 2018 → 30 Jun 2023Funding: Nonprofit institution or equivalents
- Effect and process evaluation of an intervention program on physical activity and sedentary behavior in castrate resistant prostate cancer patientsFrom1 Oct 2017 → 30 Sep 2022Funding: FWO fellowships
- PEACE V: a randomized phase III trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM)From1 Jan 2017 → 31 Oct 2021Funding: BOF - Doctoral projects
- A randomized phase II trial for the Treatment of Oligorecurrent nodal prostate cancer: TOREN-trial.From1 Jan 2017 → 31 Dec 2021Funding: Foundations, funds and other with scientific goal
Publications
41 - 50 of 242
- Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT(2019)
Authors: Alfonso Gomez-Iturriaga, Francisco Casquero Ocio, Piet Ost, Iratxe Fernandez, Emilia Rodeno, Roberto Llarena, Jorge Garcia-Olaverri, Roberto Ortiz de Zarate, Jon Cacicedo, Alina Ahtamon, et al.
- Re: Gaetan Devos, Gert De Meerleer, Steven Joniau. Have we entered the era of imaging before salvage treatment for recurrent prostate cancer? Eur Urol 2019;76:265-7(2019)
Authors: Aurélie De Bruycker, Valerie Fonteyne, Piet Ost
Pages: E146 - E147 - Nodal oligorecurrent prostate cancer : anatomic pattern of possible treatment failure in relation to elective surgical and radiotherapy treatment templates(2019)
Authors: Aurélie De Bruycker, Elise De Bleser, Karel Decaestecker, Valerie Fonteyne, Nicolaas Lumen, Pieter De Visschere, Kathia De Man, Louke Delrue, Bieke Lambert, Piet Ost
Pages: 826 - 833 - Assessing the role and optimal duration of hormonal treatment in association with salvage radiation therapy after radical prostatectomy : results from a multi-institutional study(2019)
Authors: Nicola Fossati, Daniele Robesti, R. Jeffrey Karnes, Matteo Soligo, Stephen A. Boorjian, Alberto Bossi, Gabriele Coraggio, Nadia Di Muzio, Cesare Cozzarini, Barbara Noris Chiorda, et al.
Pages: 443 - 449 - Exploration of the urinary proteome in the search for new biomarkers for prostate cancer : a promising role for extracellular vesicles(2019)Volume: 201
Authors: Glenn Vergauwen, Jan Van Deun, Edward Geeurickx, Joeri Tulkens, lkka Miinalainen, Pekka Rappu, Jyrki Heino Oulu, Finland, Piet Ost, An Hendrix, Nicolaas Lumen
Number of pages: 1 - What is oligometastatic prostate cancer?(2019)
Authors: Michael Fraser, Bridget Koontz, Urban Emmenegger, Gert De Meerleer, Vincent Khoo, Felix Feng, Niall M. Corcoran, Christopher M. Hovens, Phuoc T. Tran, Piet Ost, et al.
Pages: 159 - 161 - REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer(2019)
Authors: Petra Seibold, Adam Webb, Miguel E. Aguado-Barrera, David Azria, Celine Bourgier, Muriel Brengues, Erik Briers, Patricia Calvo-Crespo, Ana Carballo, Ananya Choudhury, et al.
Pages: 59 - 67 - Implementation of a lifestyleU+2010based clinical pathway in daily clinical practice in men undergoing androgen deprivation therapy for prostate cancer(2019)Volume: 15
Authors: Anniek Bruggeman, BARBARA VAN RUYMBEKE, Stefanie Mortier, Anneleen Raes, Martine De Muynck, Nicolaas Lumen, Piet Ost
Number of pages: 1 - A phase III randomized-controlled, single-blind trial to improve quality of life with stereotactic body radiotherapy for patients with painful bone metastases (ROBOMET)(2019)
Authors: Carole Mercier, Piet Dirix, Piet Ost, Charlotte Billiet, Ines Joye, Peter Vermeulen, Yolande Lievens, Dirk Verellen
- Immune checkpoint blockade for organ transplant patients with advanced cancer : how far can we go?(2019)
Authors: Pauline De Bruyn, Dirk Van Gestel, Piet Ost, Vibeke Kruse, Lieve Brochez, Hans Van Vlierberghe, Arnaud Devresse, Véronique del Marmol, Alain Le Moine, Sandrine Aspeslagh
Pages: 54 - 64